Lupin receives FDA approval for generic Rifadin® capsules

Pharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (FDA).

Read the press release here.

Source: Lupin Limited